Back to Search
Start Over
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
- Source :
-
Lancet . 11/24/2012, Vol. 380 Issue 9856, p1819-1828. 10p. - Publication Year :
- 2012
Details
- Language :
- English
- ISSN :
- 01406736
- Volume :
- 380
- Issue :
- 9856
- Database :
- Academic Search Index
- Journal :
- Lancet
- Publication Type :
- Academic Journal
- Accession number :
- 108077887
- Full Text :
- https://doi.org/10.1016/S0140-6736(12)61769-3